IRON - Disc Medicine Inc

-

$undefined

N/A

(N/A)

Disc Medicine Inc NasdaqGM:IRON Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Location: 321 Arsenal Street, Watertown, MA, 02472, United States | Website: https://www.discmedicine.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

959.3M

Cash

694.7M

Avg Qtr Burn

-25.43M

Short % of Float

12.07%

Insider Ownership

10.58%

Institutional Own.

98.93%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Bitopertin Details
erythropoietic porphyrias, X-linked protoporphyria

NDA

Submission

DISC-0974 Details
Myelofibrosis, Anemia, Chronic kidney disease

Susp. Mover™

Phase 2

Data readout

DISC-3405 (formerly MWTX-003) Details
Polycythemia vera, Cancer, Blood cancer

Phase 2

Initiation

Bitopertin Details
Anemia, Rare genetic disease

Phase 1/2

Update

GEM103 Details
Age-related macular degeneration

Failed

Discontinued

GEM103 Details
Wet age-related macular degeneration , Age-related macular degeneration

Failed

Discontinued